Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined Application of Isothiocyanate Compounds and Hormone Drugs

A technology of isothiocyanate and isothiocyanate, applied in the field of pharmaceutical preparations, can solve problems such as no effective therapeutic drugs

Active Publication Date: 2021-02-26
JC (WUXI) CO INC
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no effective treatment drug, which is a worldwide problem and the main cause of death of prostate cancer patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined Application of Isothiocyanate Compounds and Hormone Drugs
  • Combined Application of Isothiocyanate Compounds and Hormone Drugs
  • Combined Application of Isothiocyanate Compounds and Hormone Drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0181] Example 1: Isothiocyanate compounds have a synergistic effect with hormone-based anticancer drugs of endocrine therapy on growth inhibition of hormone-dependent prostate cancer cells

[0182] Table 1 IC of LNCaP cells treated with abiraterone and different isothiocyanates 50 CI

[0183]

[0184]

[0185] It can be seen from Table 1 that the anti-prostate cancer hormone drug abiraterone, phenylethyl isothiocyanate, cyclohexyl isothiocyanate, and 4-chlorobenzyl isothiocyanate have a combined effect on hormone-dependent prostate cancer. Cancer cells, LNCaP, have a synergistic effect.

[0186] Table 2 IC of enzalutamide and different isothiocyanates in LNCaP cells 50 CI

[0187]

[0188] It can be seen from Table 2 that the anti-prostate cancer hormone drug enzalutamide, phenylethyl isothiocyanate, and benzyl isothiocyanate have a synergistic effect on the hormone-dependent prostate cancer cell LNCaP in combination.

[0189] Table 3 IC of LNCaP cells treated by...

Embodiment 2

[0196] Example 2: Isothiocyanate compounds have a synergistic effect with hormone-based anticancer drugs of endocrine therapy on growth inhibition of hormone-independent prostate cancer cells

[0197] Table 5 IC of DU145 cells in the action of abiraterone and phenylethyl isothiocyanate 50 CI

[0198]

[0199] Table 6 IC of Abiraterone and phenylethyl isothiocyanate on PC-3 cells 50 CI

[0200]

[0201] It can be seen from Table 5 and Table 6 that the combination of anti-prostate cancer hormone drug abiraterone and phenylethyl isothiocyanate has a synergistic effect on hormone-independent prostate cancer cells DU145 and PC-3.

[0202] Table 7 IC of DU145 cells treated with enzalutamide and phenylethyl isothiocyanate 50 CI

[0203]

[0204] Table 8 IC of PC-3 cells treated with enzalutamide and phenylethyl isothiocyanate 50 CI

[0205]

[0206] It can be seen from Table 7 and Table 8 that the anti-prostate cancer hormone drug enzalutamide and phenylethyl isothi...

Embodiment 3

[0210] Example 3: The effect of phenylethyl isothiocyanate combined with endocrine therapy on patients with advanced prostate cancer

[0211] (1) Volunteer male, 61 years old

[0212] Diagnosed with advanced prostate cancer at the end of March 2011, PSA 145.4;

[0213] In April 2011, PEITC-enhanced endocrine therapy was started: Oral Casodex (bicalutamide) 50mg, 1 time / day, oral PEITC 60mg, 3 times / day, intramuscular injection of Nored (goserelin) 3.6mg, 1 times / 28 days;

[0214] From July 7 to September 29, 2011, radiotherapy, endocrine therapy was suspended;

[0215] On September 30, 2011, PEITC enhanced endocrine therapy was resumed;

[0216] On June 14, 2012, tPSA was below the detection limit.

[0217] Pathological diagnosis results on March 30, 2011: 13 needles of prostate puncture, 1-13 needles showed prostate cancer, Gleasonscore 4+5 (sum9), some signet ring cells were seen. The proportion of tumors in the 1st, 2nd, 4th, 5th, 8th, 12th, and 13th injections was mor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to combined application of an isothiocyanate compound and a hormone medicine, and particularly discloses a composition. The composition comprises (A) an effective dose of a first active ingredient for treatment, namely the isothiocyanate compound or a derivative thereof, and (B) the effective dose of a second active ingredient for treatment, namely a hormone anti-cancer medicine for an internal secretion method, wherein the mass ratio of the first active ingredient to the second active ingredient is (1-1000):(1000-1). The invention also discloses combination of the active components, a medicine box, a medicine composition and application of the medicine composition in preparation of a prostate cancer-resisting medicine. The composition, the combination of the active ingredients and the medicine box play an excellent role of inhibiting the growth of prostate cancer cells.

Description

technical field [0001] The present invention relates to the field of pharmaceutical preparations, in particular to a composition comprising isothiocyanate compounds or derivatives thereof and hormone-based anticancer drugs for endocrine therapy, a kit and a pharmaceutical composition, and its preparation for the treatment of prostate cancer application in medicine. Background technique [0002] Prostate cancer (PCa) is the most common malignant tumor of the male reproductive system, and it is currently the third most common male cancer, and it has shown an accelerating upward trend in recent years. Prostate cancer is seriously affecting the quality of life and life expectancy of men over 50 years old in my country. Due to insufficient understanding and attention to prostate cancer, early detection, early detection, and early treatment have not been achieved (in developed countries, the inspection of prostate cancer is already one of the must-check items for middle-aged and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61P35/00A61K31/26
Inventor 程景才张春侠程志维
Owner JC (WUXI) CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com